202 related articles for article (PubMed ID: 20833148)
1. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.
Hatfield MJ; Tsurkan L; Hyatt JL; Yu X; Edwards CC; Hicks LD; Wadkins RM; Potter PM
Br J Pharmacol; 2010 Aug; 160(8):1916-28. PubMed ID: 20649590
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
4. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
5. Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
Xie M; Yang D; Wu M; Xue B; Yan B
Drug Metab Dispos; 2003 Jan; 31(1):21-7. PubMed ID: 12485949
[TBL] [Abstract][Full Text] [Related]
6. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
7. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
8. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
10. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
11. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM
Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028
[TBL] [Abstract][Full Text] [Related]
13. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Hicks LD; Hyatt JL; Stoddard S; Tsurkan L; Edwards CC; Wadkins RM; Potter PM
J Med Chem; 2009 Jun; 52(12):3742-52. PubMed ID: 19534556
[TBL] [Abstract][Full Text] [Related]
14. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
15. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
16. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
18. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
[TBL] [Abstract][Full Text] [Related]
20. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
